title: Management of chronic hepatitis B in the HIV-infected patient.
abstract: Coinfection with HIV and hepatitis B virus (HBV) is common because of their shared modes of transmission. HIV infection alters the natural history of HBV infection, leading to more severe liver disease, decreased hepatitis B e antigen seroconversion, and higher HBV DNA levels. Furthermore, end-stage liver disease has emerged as a common cause of morbidity and mortality in HIV-infected persons receiving HAART. For these reasons, it is important to vaccinate susceptible persons against HBV infection and to diagnose and treat chronic hepatitis B in HIV-infected persons. The treatment plan for chronic hepatitis B needs to be individualized based on the stage of both viral infections and the available options. It is anticipated that we are entering a period of combination therapy for chronic hepatitis B, but the ideal combination needs to be elucidated.
authors.affiliation: Johns Hopkins University, Baltimore, Maryland, USA.
authors.forename: Chloe L
authors.initials: CL
authors.lastname: Thio
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000465:Algorithms; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003663:Decision Trees; D004359:Drug Therapy, Combination; D015658:HIV Infections; D019694:Hepatitis B, Chronic / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000068698:Tenofovir
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D019259:Lamivudine; D000068698:Tenofovir; D000225:Adenine; C106812:adefovir dipivoxil